This database contains 32 studies, archived under the term: "radionuclide imaging"
Click here to filter this large number of results.
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, Vladimir,
Salloway, Stephen,
van Dyck, Christopher H.,
Dubois, Bruno,
Andreasen, Niels,
Brody, Mark,
Curtis, Craig,
Soininen, Hilkka,
Thein, Stephen,
Shiovitz, Thomas,
Pilcher, Gary,
Ferris, Steven,
Colby, Susan,
Kerselaers, Wendy,
Dockens, Randy,
Soares, Holly,
Kaplita, Stephen,
Luo, Feng,
Pachai, Chahin,
Bracoud, Luc,
Mintun, Mark,
Grill, Joshua D.,
Marek, Ken,
Seibyl, John,
Cedarbaum, Jesse M.,
Albright, Charles,
Feldman, Howard H.,
Berman, Robert M.
Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]
Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease
Smith, Gwenn S.,
Laxton, Adrian W.,
Tang-Wai, David F.,
McAndrews, Mary Pat,
Diaconescu, Andreea Oliviana,
Workman, Clifford I.,
Lozano, Andres M.
Background: The importance of developing unique, neural circuitry-based treatments for the cognitive and neuropsychiatric symptoms of Alzheimer disease (AD) was the impetus for a phase I study of deep brain stimulation (DBS) in patients with AD that targeted the fornix.; Objective: To test the hypotheses that DBS would increase cerebral glucose metabolism in cortical and […]
Evaluation of the regional cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer’s disease using 3DSRT
Kimura, Noriyuki,
Kumamoto, Toshihide,
Masuda, Teruaki,
Hanaoka, Takuya,
Okazaki, Toshio,
Arakawa, Ryuki
Background: We attempt to evaluate objectively the regional cerebral blood flow (rCBF) changes during long-term donepezil therapy and the relationship between the clinical response and rCBF change in patients with Alzheimer’s disease (AD).; Patients and Methods: Thirty-one patients with mild-to-moderate AD (11 men, 20 female; mean age, 76.2 ± 6.7 years) were treated with donepezil […]
Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study
Kasuya, Masashi,
Meguro, Kenichi,
Okamura, Nobuyuki,
Funaki, Yoshihito,
Ishikawa, Hiroyasu,
Tanaka, Naofumi,
Iwata, Ren,
Yanai, Kazuhiko
The aim of the study was to predict donepezil responders among patients with Alzheimer disease (AD) based on cognitive tests and positron emission tomography. The Mini-Mental State Examination, Digit Symbol subtest (DigSm) of Wechsler Adult Intelligence Scale Revised, and Trail-Making Test A were administered for 80 patients with AD to assess global function, attention, and […]
Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
Farlow, Martin,
Arnold, Steven E.,
van Dyck, Christopher H.,
Aisen, Paul S,
Snider, B. Joy,
Porsteinsson, Anton P.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon,
Sethuraman, Gopalan,
Demattos, Ronald B.,
Mohs, Richard,
Paul, Steven M.,
Siemers, Eric R.
Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer’s disease. Cognitive measures were also obtained.; Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer’s disease received placebo or antibody (100 mg every 4 weeks, 100 […]
Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD
Silverman, Daniel H. S.,
Geist, Cheri L.,
Kenna, Heather A.,
Williams, Katherine,
Wroolie, Tonita,
Powers, Bevin,
Brooks, John,
Rasgon, Natalie L.
Differential cerebral metabolic effects of various hormone therapy formulations, and their associations with cognitive status, remain to be established. The principal aim of the current study was to assess relationships between regional cerebral metabolism and estrogen-based hormone therapies. Postmenopausal women (n=53) at elevated risk for Alzheimer’s disease (AD) were on estrogen-containing hormone therapy for at […]
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, Juha O.,
Brooks, David J.,
Rossor, Martin N.,
Fox, Nick C.,
Bullock, Roger,
Klunk, William E.,
Mathis, Chester A.,
Blennow, Kaj,
Barakos, Jerome,
Okello, Aren A.,
Rodriguez Martinez de Liano, Sofia,
Liu, Enchi,
Koller, Martin,
Gregg, Keith M.,
Schenk, Dale,
Black, Ronald,
Grundman, Michael
Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]
A multi-center randomized proof-of-concept clinical trial applying ¹⁸FFDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease
Tzimopoulou, Sofia,
Cunningham, Vincent J.,
Nichols, Thomas E.,
Searle, Graham,
Bird, Nick P.,
Mistry, Prafull,
Dixon, Ian J.,
Hallett, William A.,
Whitcher, Brandon,
Brown, Andrew P.,
Zvartau-Hind, Marina,
Lotay, Narinder,
Lai, Robert Y. K.,
Castiglia, Mary,
Jeter, Barbara,
Matthews, Julian C.,
Chen, Kewei,
Bandy, Dan,
Reiman, Eric M.,
Gold, Michael,
Rabiner, Eugenii A.,
Matthews, Paul M.
Here we report the first multi-center clinical trial in Alzheimer’s disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months treatment with the PPARγ agonist Rosiglitazone XR versus placebo in 80 mild to moderate AD patients. Secondary objectives included testing for reduction […]
Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project
Satoh, Masayuki,
Ishikawa, Hiroyasu,
Meguro, Kenichi,
Kasuya, Masashi,
Ishii, Hiroshi,
Yamaguchi, Satoshi
Deficits in the cholinergic system are pronounced in dementia with Lewy bodies (DLB) and are more severe in patients with visual hallucinations (VHs). The aim is to identify the occipital glucose metabolism patterns by positron emission tomography (PET) and the changes following donepezil treatment. 13 DLB patients with VHs were enrolled in the study. After […]